PATENT CLAIM ANALYSIS

Application Number: 16322264
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-06
Patent Classification: ["514", "235800"]

Abstract:
Pyrimidine derivatives of formula (I) wherein: Z is a direct bond or —(CH 2 ) n — wherein n is 1 or 2; one of X and Y is N, CH or CF, and the other of X and Y is CH; one of R 1  and R 2  is selected from —NHR, —NR 2 , —OR, —SR, —S(O)R, —S(O) 2 R and a group of the following formula (A) and the other of R 1  and R 2  is selected from —NHR′, —OH, —OR′ and a group of the above formula (A); R is unsubstituted C 1 -C 6  alkyl; R′ is a group selected from C 1 -C 6  alkyl, 5- to 12-membered aryl and C 3 -C 6  cycloalkyl, which group is unsubstituted or substituted; W is —(CH 2 ) m —, —CH 2 —O—CH 2 —, —CH 2 —S—CH 2 — or —CH 2 —S(O) 2 —CH 2 —; p is 1, q is an integer of 1-6 and V is N; or p is 1, q is 0 and V is CH; or p is 0, q is 0 and V is N; r is 0 or 1; and R 3  is —(CH 2 ) s —NH 2  or —(CH 2 ) s —OH wherein s is 0 or an integer of 1 to 4; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

Claim (Index 6):
A compound according to  claim 1  which is selected from:\n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-(isopentylamino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-(((1r,4r)-4-hydroxycyclohexyl)amino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-((2-morpholinoethyl)amino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-((4-hydroxybutyl)amino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-(isobutylamino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(4-Aminomethyl)piperidin-1-yl)-4-(isobutylamino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 6\u2032-Fluoro-1\u2032-((4-(isopentylamino)-2-(pyrrolidin-1-yl)pyrimidin-5-yl)methyl)spiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 6\u2032-Fluoro-1\u2032-((4-(isobutylamino)-2-morpholinopyrimidin-5-yl)methyl)spiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-morpholinopyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-((3-methoxypropyl)amino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-((3-methoxypropyl)amino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((4-(3-Aminopyrrolidin-1-yl)-2-((4-hydroxybutyl)amino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-((2-(3-Aminopyrrolidin-1-yl)-4-(1,1-dioxidothiomorpholino)pyrimidin-5-yl)methyl)-6\u2032-fluorospiro[cyclopropane-1,3\u2032-indolin]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-(4-methanesulfonylpiperazin-1-yl)pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1-[2-(3-Aminopyrrolidin-1-yl)-5-({6\u2032-fluoro-2\u2032-oxo-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-1\u2032-yl}methyl)pyrimidin-4-yl]pyrrolidine-2-carboxamide; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-[(4-hydroxybutyl)sulfanyl]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[4-(4-Acetylpiperazin-1-yl)-2-(3-aminopyrrolidin-1-yl)pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-[(2-methanesulfonylethyl)amino]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-[(5-hydroxypentyl)amino]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-[(4-hydroxycyclohexyl)amino]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclobutane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1l-yl)-4-(5-hydroxypent-1-yn-1-yl)pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-(3-fluoropropoxy)pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1l-yl)-4-{[(oxan-4-yl)methyl]amino}pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(4-Aminopiperidin-1-yl)-4-[(4-hydroxybutyl)amino]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-({2-[(2-Aminoethyl)amino]-4-[(4-hydroxybutyl)amino]pyrimidin-5-yl}methyl)-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-[(2-hydroxyethyl)amino]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-[(3-hydroxypropyl)amino]pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-(propylamino)pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; and \n 1\u2032-{[2-(3-Aminopyrrolidin-1-yl)-4-(ethylamino)pyrimidin-5-yl]methyl}-6\u2032-fluoro-1\u2032,2\u2032-dihydrospiro[cyclopropane-1,3\u2032-indole]-2\u2032-one; \n and the pharmaceutically acceptable salts thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 99.0
- Lexical Diversity: 3.23077
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15517290', '14357293', '14435604', '15023465', '14971120']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8114790598859303
- 35 USC 102 Novelty (BERT): 0.5446843789381667
- Combined Prediction Score: 0.7847995917911539
- Mean Citation Score: 328.202194
- Max Citation Score: 397.06805
- Similarity Product: 320.60800415399376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test